The combination of the anti-EGFR antibody cetuximab with irinotecan or the FOLFIRI regimen has improved treatment outcomes in RAS and BRAF wild-type metastatic colorectal cancers [46]. Here, EGFR is linked to metastatic colorectal cancer.